Review of Caplan (1991) on cell-based therapeutic technology using Mesenchymal Stem Cells

Area of Science:

• Regenerative Medicine
• Cell Therapy
• Tissue Engineering

Background:

• Mesenchymal stem cells (MSCs) were first described in 1991 as a cell source for self-cell repair.
• Initially believed to regenerate tissue directly at transplant sites, the understanding of MSCs has evolved.
• Current clinical applications include treating cartilage defects, liver cirrhosis, and spinal cord injuries.

Purpose of the Study:

• To review the evolution of Mesenchymal Stem Cells (MSCs) research and applications.
• To highlight the shift in understanding MSCs from stem cells to medicinal signaling cells.
• To discuss the future potential of MSCs in regenerative medicine.

Main Methods:

• Review of the seminal 1991 publication on Mesenchymal Stem Cells (MSCs).
• Analysis of subsequent research on MSCs for tissue regeneration.
• Examination of current clinical uses and evolving therapeutic concepts.

Main Results:

• MSCs are a key cell source in regenerative medicine, used clinically for diverse conditions.
• The concept of MSCs has shifted to 'medicinal signaling cells' due to their indirect regenerative effects.
• Significant advancements in tissue regeneration methods using MSCs have been reported since 1991.

Conclusions:

• Mesenchymal stem cells (MSCs), or medicinal signaling cells, are vital for regenerative medicine.
• Their therapeutic applications are expanding, with significant future potential.
• Continued research will likely broaden the use of MSCs for tissue repair and disease treatment.